{"id":63030,"date":"2026-04-13T20:42:13","date_gmt":"2026-04-13T12:42:13","guid":{"rendered":"https:\/\/flcube.com\/?p=63030"},"modified":"2026-04-13T20:42:14","modified_gmt":"2026-04-13T12:42:14","slug":"abbvie-secures-nmpa-label-expansion-for-rinvoq-in-china-clarifying-use-in-uc-and-crohns-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63030","title":{"rendered":"AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease"},"content":{"rendered":"\n

AbbVie Inc.<\/strong> (NYSE: ABBV<\/a>) has announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> has approved a label update<\/strong> for its JAK inhibitor, Rinvoq (upadacitinib)<\/strong>, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC)<\/strong> and Crohn’s disease (CD)<\/strong>. The updated label provides clear guidance on patient selection, specifying the sequence of prior therapies required before initiating treatment.<\/p>\n\n\n\n

Regulatory Update & Indication Details<\/h2>\n\n\n\n
Indication<\/th>Updated NMPA Label Guidance<\/th><\/tr><\/thead>
Ulcerative Colitis (UC)<\/strong><\/td>For adults with inadequate response, loss of response, or intolerance to at least one conventional therapy or biologic agent<\/strong>, where TNF inhibitor use is not clinically recommended.<\/td><\/tr>
Crohn’s Disease (CD)<\/strong><\/td>For adults with inadequate response, loss of response, or intolerance to at least one conventional therapy or biologic agent<\/strong>, where TNF inhibitor use is not clinically recommended.<\/td><\/tr>
Drug Class<\/strong><\/td>Oral JAK inhibitor<\/td><\/tr>
China Market Entry<\/strong><\/td>2022<\/td><\/tr>
Initial China Approvals<\/strong><\/td>UC (Feb 2023), CD (Jun 2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Significance<\/h2>\n\n\n\n